Drug Trial Radar · NCT06961006
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
May 29, 2025
Primary completion
Jul 22, 2028
Study completion Sep 5, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers want to learn if intismeran autogene with pembrolizumab can stop advanced melanoma from growing or spreading. Melanoma is a type of skin cancer. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. A standard (or usual) treatment for advanced melanoma is immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. Intismeran autogene is a study treatment designed to help a person's immune system attack their specific cancer. Pembrolizumab is an immunotherapy. The goal of this study is to learn if people who receive intismeran autogene with pembrolizumab live longer without the cancer growing or spreading than people who receive placebo with pembrolizumab. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment.
Conditions
- Malignant Melanoma
Interventions
Intismeran autogeneBiological
IM injection
PembrolizumabBiological
IV infusion
PlaceboOther
IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Up to approximately 36 months
Locations
38 sites in 12 countries. Site status is shown where the registry gives one.
Highlands Oncology Group ( Site 4042)
Springdale, Arkansas
UCSF Medical Center at Mission Bay ( Site 4044)
San Francisco, California
John Theurer Cancer Center at Hackensack University Medical Center ( Site 4047)
Hackensack, New Jersey
Inova Schar Cancer Institute ( Site 4046)
Fairfax, Virginia
Fred Hutchinson Cancer Center ( Site 4041)
Seattle, Washington
Blacktown Hospital ( Site 2001)
Blacktown, New South Wales, Australia
Melanoma Institute Australia ( Site 2000)
Wollstonecraft, New South Wales, Australia
One Clinical Research ( Site 2002)
Nedlands, Western Australia, Australia
William Osler Health System (Brampton Civic Hospital) ( Site 2023)
Brampton, Ontario, Canada
Sunnybrook Research Institute ( Site 2022)
Toronto, Ontario, Canada
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Dermatology Department ( Site 2042)
Nice, Alpes-Maritimes, France
Hôpital Saint-Louis ( Site 2041)
Paris, Île-de-France Region, France
Gustave Roussy ( Site 2040)
Villejuif, Île-de-France Region, France
Universitaetsklinikum Hamburg-Eppendorf ( Site 2060)
Hamburg, Germany
NCT ( Site 2065)
Heidelberg, Baden-Wurttemberg, Germany
Universitätsklinikum Frankfurt Goethe-Universität ( Site 2063)
Frankfurt am Main, Hesse, Germany
Universitaetsklinikum Koeln ( Site 2064)
Cologne, North Rhine-Westphalia, Germany
Universitaetsklinikum Essen ( Site 2061)
Essen, North Rhine-Westphalia, Germany
European Interbalkan Medical Center ( Site 2081)
Thessaloniki, Greece
General Hospital of Athens "Laiko" ( Site 2080)
Athens, Attica, Greece
Metropolitan Hospital ( Site 2082)
Athens, Attica, Greece
HaEmek Medical Center ( Site 3003)
Afula, Israel
Hadassah Medical Center ( Site 3001)
Jerusalem, Israel
Rabin Medical Center ( Site 3002)
Petah Tikva, Israel
Sheba Medical Center ( Site 3000)
Ramat Gan, Israel
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 3020)
Naples, Italy
Istituto Oncologico Veneto IRCCS ( Site 3022)
Padova, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 3023)
Roma, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 3021)
Milan, Milano, Italy
Harbour Cancer & Wellness ( Site 3040)
Auckland, New Zealand
Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 3061)
Poznan, Greater Poland Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 3060)
Warsaw, Masovian Voivodeship, Poland
Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 4001)
Lisbon, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 4000)
Porto, Portugal
Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 4002)
Lisbon, Lisbon District, Portugal
Hospital Universitari Vall d Hebron ( Site 3081)
Barcelona, Spain
Hospital Clínic Barcelona ( Site 3080)
Barcelona, Spain
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 3082)
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.